Entering text into the input field will update the search result below

FDA accepts Stealth Bio's Pre-NDA meeting request for elamipretide

  • Stealth BioTherapeutics (NASDAQ:MITO) plans to meet with the FDA's Division of Cardiology and Nephrology (DCN) regarding its upcoming NDA submission for elamipretide for the treatment of cardiomyopathy in Barth syndrome.
  • This Type B Pre-NDA meeting follows prior interactions during which

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
MITO--
Stealth BioTherapeutics Corp